Masuda H, Battifora H, Yokota J, Meltzer S, Cline M J
Department of Medicine, University of California, Los Angeles 90024.
Mol Biol Med. 1987 Aug;4(4):213-27.
DNAs from 253 fresh human tumors of 38 different types were hybridized with 17 different oncogene probes. The analysis demonstrated unique associations between amplification of specific oncogenes and specific types of tumors. In a large number of cases it was determined that amplified oncogenes occurred in 10 to 20% of tumors with the following specific associations: c-myc in adenocarcinomas, squamous carcinomas and sarcomas but not hematologic malignancies; c-erbB2 in adenocarcinomas, particularly breast cancers; c-erbB1 in squamous carcinomas; N-myc in neuroblastomas. A small number of cases suggested other specific associations: amplified c-myb in breast cancers; amplified c-ras-Ha and c-ras-Ki in ovarian carcinomas. In addition, there was a correlation between amplification of c-myc and the clinical stage of adenocarcinomas, and amplification of c-erbB2 and the clinical stage and lymph node involvement of breast cancers.
来自38种不同类型的253例新鲜人类肿瘤的DNA与17种不同的癌基因探针进行杂交。分析表明特定癌基因的扩增与特定类型肿瘤之间存在独特关联。在大量病例中确定,扩增的癌基因出现在10%至20%的肿瘤中,具有以下特定关联:c-myc在腺癌、鳞状细胞癌和肉瘤中出现,但在血液系统恶性肿瘤中未出现;c-erbB2在腺癌中出现,尤其是乳腺癌;c-erbB1在鳞状细胞癌中出现;N-myc在神经母细胞瘤中出现。少数病例提示了其他特定关联:乳腺癌中c-myb扩增;卵巢癌中c-ras-Ha和c-ras-Ki扩增。此外,c-myc的扩增与腺癌的临床分期之间存在相关性,c-erbB2的扩增与乳腺癌的临床分期和淋巴结受累情况之间存在相关性。